Researchers investigating the 'radius gap' in exoplanet sizes found that younger mini-Neptunes shrink drastically over billions of years, leaving behind solid cores and becoming super-Earths. As planets age, their gas is stripped away, shifting the radius gap between rocky super-Earths and larger, gas-shrouded planets.
Researchers at Newcastle University discovered that tiny pieces of genetic material, miR-424-5p, increase in early stages of heart disease in type 1 diabetes patients. This biomarker has the potential to define additional therapeutic options to help patients with type 1 diabetes.
Researchers found no significant differences in cardiovascular events or major bleeding between patients taking 81mg or 325mg daily doses of aspirin. Long-term adherence was better among those taking the lower dose.
The study analyzed over 36,000 LAAO procedures performed with the WATCHMAN device in older, higher-risk patients with atrial fibrillation. At one year, the estimated 1.53% ischemic stroke rate was lower than predicted by stroke risk scores, suggesting effective stroke prevention.
Researchers found that left atrial appendage occlusion significantly reduced stroke risk by 33% in patients with AFib or atrial flutter. The procedure, performed during heart surgery, added less than 10 minutes to the operation and demonstrated long-term safety.
A new study by Rutgers researchers found that COVID-19 can trigger a rare recurrence of upper extremity blood clots, requiring vigilant monitoring and treatment. Patients with a history of deep vein thrombosis or chronic medical conditions are at higher risk for recurrence.
A large international study led by McMaster University found that removing the left atrial appendage significantly cuts the risk of strokes by more than one-third in patients with atrial fibrillation. The procedure is simple, quick, and safe for the majority of heart surgery patients with this condition.
A study presented at ACC.21 found that low- and high-dose aspirin achieved similar health benefits for those with cardiovascular disease, including reduced death and hospitalization rates. However, the higher dose group was more likely to switch doses and discontinue use due to tolerability concerns.
Researchers found that apixaban reduced blood clot formation around implanted valves with no increased bleeding risk. However, a subset of patients showed higher rates of non-cardiovascular death without anticoagulation indication.
The PARADISE-MI trial found sacubitril/valsartan to be well-tolerated and associated with a trend toward improvement in secondary endpoints. However, it did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril.